Kornimate/medical-research-clean huggingface dataset:
post stroke epileptic seizures risk forecast

Conditions: Stroke; Post Stroke Seizure; Post Stroke Epilepsy

Summary: improve the effectiveness of treatment and prognosis in patients with cerebrovascular accident by early detection of the risk of developing epileptic seizures.


Eligibility criteria:
inclusion criteria: * informed consent to participate in the study signed by the patient / relative of the patient / the legal representative of the patient * age over 18 years * stroke, confirmed by neuroimaging * light to moderate stroke (score on national institutes of health stroke scale). exclusion criteria: * recanalization therapy * previous epileptic seizures and history of epilepsy * psychiatric diseases in history * previous stroke * traumatic brain injury * brain tumors. * inflammatory and infectious diseases * decompensated physical illness. * pregnancy.

Keywords: stroke epilepsy seizure eeg
evaluation of cardiovascular effects of smoking cessation in hiv patients

Conditions: HIV Infections; Smokers

Summary: we will conduct a sub-study of "an innovative telephone intervention for hiv+ smokers," (nct00502827) conducted by drs. gritz, vidrine, and others. this is a randomized, prospective trial that will evaluate a cellular phone delivered counseling intervention versus standard of care for smoking cessation. in our sub-study, we will evaluate rates of progression in atherosclerosis in hiv/aids patients who quit smoking versus those who continue smoking by measuring carotid intima-media thickness(cimt) and biomarkers of atherosclerosis at time point baseline, 1 year, and 3 year. the biomarkers measured include high-sensitivity creactive protein, homocysteine, and il-6. we will also evaluate rates of progression of cimt in those who quit smoking versus those who continue smoking, based on race, sex, state of hiv disease, comorbid diseases, and lipid profile.

hiv/aids patients may have an increased risk of myocardial infarction. traditional risk factors for coronary artery disease, including cigarette smoking, likely play a large role. the prevalence of smoking in the hiv patient population is higher than the general population. we will conduct a sub-study of "an innovative telephone intervention for hiv+ smokers," (nct00502827) conducted by drs. gritz, vidrine, and others. this is a randomized prospective trial that will evaluate a cellular phone delivered counseling intervention versus standard of care for smoking cessation. in our sub-study, we will evaluate rates of progression in atherosclerosis in hiv/aids patients who quit smoking versus those who continue smoking by measuring carotid intima-media thickness(cimt) and biomarkers of atherosclerosis at time point baseline, 1 year, and 3 year. the biomarkers measured include high-sensitivity creactive protein, homocysteine, and il-6. we will also evaluate rates of progression of cimt in those who quit smoking versus those who continue smoking based on race, sex, state of hiv disease, comorbid diseases and lipid profile. the central hypothesis is that smoking cessation win slow the atherosclerosis progression in hiv patients. a successful behavioral intervention is being evaluated in the parent study. the goal of this sub-study is to assess the effect of a modifiable coronary artery disease risk factor, smoking, in hiv/aids patients through this collaboration of cardiovascular expertise and metrics.

Eligibility criteria:
inclusion criteria: * patients who meet eligibility criteria for "an innovative telephone intervention for hiv-positive smokers". * patients who consent to the sub-study. * patients who are able to participate in the study for 3 years. exclusion criteria: * patients with a history of coronary bypass surgery, percutaneous coronary intervention, valve replacement, pacemaker or defibrillator implantation.

Keywords: hiv infected smokers hiv
irm cognition in patients with head trauma

Conditions: Brain-damaged Patients

Summary: longitudinal descriptive study of a cohort of twenty brain-damaged patients for a two years period.

the following data are collected in 3 months, 12 months then 24 months after the accident with followed data collection : * clinical, neuropsychological assessments * diffusion magnetic resonance imaging (mri) for the reconstruction of anatomical pathways * functional imaging data.

Eligibility criteria:
inclusion criteria: * adult patients, over the age of 18. * mild traumatic brain injury (initial glasgow score between 9 and 12) * severe brain injury (initial glasgow score between 3 and 8), * diffuse axonal injury and/or focal lesions. exclusion criteria: * patients with mri contraindications, * antecedents of brain lesions, * important lesions of the lobes and cortex on cerebral ct, * anoxic lesions related to cardiorespiratory arrest, * must be able to perform neuropsychological tests, * visual and auditory impairments. * aphasia

Keywords: craniocerebral injury mild and severe brain traumatic injury neuropsychological abilities clinical assessment anatomical and functional imaging
efficacy and safety of gadobutrol 1.0 molar (gadovist) for breast mri

Conditions: Breast Cancer; Diagnostic Imaging

Summary: the purpose of this study is to look at the efficacy (how does it work) and safety of gadobutrol when used for obtaining mr images of both breasts.women with a recent diagnosis of breast cancer by mammogram (x-ray examination of the breasts) may benefit from mri of the breasts as mri may detect additional breast cancers.


Eligibility criteria:
inclusion criteria: * recent histologically proven diagnosis of breast cancer after having obtained x-ray mammography (xrm) of both breasts (according to american college of radiology \[acr\] and performed no longer than 6 weeks prior to enrollment into the study) and has been referred for a contrast-enhanced magnetic resonance mammography (mrm) prior to surgery of the breast. * if female, a digital xrm is required if any of the following criteria is met: 1. patient is younger than 50 years; 2. patient has heterogeneously or extremely dense breasts; 3. is not post-menopausal (post-menopause defined as at least 12 months prior to inclusion without menstruation). * if female of childbearing potential, mrm should be performed on the 7-14th day of the menstrual cycle. * has an estimated glomerular filtration rate (egfr) value \>/= 60 ml/min/1.73m\^2 derived from a serum creatinine result within 2 weeks prior to study enrollment. exclusion criteria: * is a female patient who is pregnant or lactating * has any contraindication to the mrm examination (e.g. metal implants, phobia) or the use of gadolinium-containing contrast agents. * has received any contrast agent within 24 hours prior to the study mrm, or is scheduled to receive any contrast agent within 24 hours after the study mrm. * has severe cardiovascular disease (e.g., known long qt syndrome, acute myocardial infarction \[\< 14 days\], unstable angina, congestive heart failure new york heart association class iv) or acute stroke (\< 48 hours)). * has acute renal insufficiency of any severity due to hepato-renal syndrome or in the peri-operative liver transplantation period or who has acute or chronic moderate or severe renal insufficiency (glomerular filtration rate \< 60 ml/min/1.73m\^2). * has received chemotherapy or hormonal therapy for breast cancer within 6 months. * has received hormone replacement therapy within 4 weeks prior to study drug administration. * is scheduled or likely to require a surgery and/or biopsy in the time period up to 24 hours following study drug application * has prior excisional biopsy or breast surgery less than 6 months before enrollment and between xrm and study mrm

Keywords: breast cancer gadobutrol-enhanced mri mammography
clinical trial with quetiapine prophylaxis postoperative delirium in high risk surgical patients

Conditions: Postoperative Delirium

Summary: double blinded clinical trial to test efficacy of quetiapine versus placebo in reducing postoperative delirium in high risk surgical patients after three days of treatment.

this study evaluates postoperative delirium in high risk surgical patients to know the incidence of postoperative delirium in patients at risk, over 65 years, treated early with prophylactic quetiapine versus placebo.

Eligibility criteria:
inclusion criteria: * greater than or equal to 65 years-old patients who will be undergoing major surgery (noncardiac) and having an equal or greater score of 5 on the scale delphi. * age: 70-79 years: 1 point; ≥80 years: 2 points. * physical activity: need for assistance, not self-sufficient: 2 point. * alcoholism: 1 point. * hearing impaired: 1 point. * history of delirium: 2 points. * emergency surgery: 1 point. * no laparoscopic surgery: 2 points. * admission critical units: 3 points. * value of c-reactive protein (crp) ≥ 10 milligrams (mg) / decilitre (dl): 1 point exclusion criteria: * allergy to quetiapine. * patients with a score less than 5 on the delphi scale. * diagnosis of delirium at admission. * cardiological diseases: corrected qt interval (qtc) ≥ 460 millisecond (msec) in men, ≥ 470 msec in women, recent myocardial infarction or cardiac decompensation, 2-3° degree atrioventricular block or history of torsades de pointes arrhythmias or ventricular arrhythmias, bradycardia... * hypokalemia ≤ 3 milliequivalent (meq) / potassium chloride (kcl). * history of drug use. * patients on antipsychotic or antidopaminergic treatment (chlorpromazine, clozapine, olanzapine, risperidone, haloperidol, quetiapine, paliperidone, amisulpride). * parkinson's disease. * test minimental ≤ 24. * corps or vascular dementia levi. * hypokinetic movement disorder. * history of neuroleptic malignant syndrome. * central anticholinergic syndrome. * epilepsy. * patients with a wight less than 50 or greater than 200 kg (kilograms).

Keywords: postoperative delirium quetiapine prophylaxis
e7070 in treating patients with solid tumors

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase i trial to study the effectiveness of e7070 in treating patients who have solid tumors.

objectives: i. determine the maximum tolerated dose of e7070 in patients with solid tumors. ii. assess the qualitative and quantitative toxicity in terms of predictability, duration, intensity, onset, reversibility, and dose relationship of this treatment regimen in this patient population. iii. determine a safe dose for phase ii evaluation. iv. assess the pharmacokinetics of this treatment regimen in these patients. v. determine any possible antitumor activity of this regimen in these patients. outline: this is a dose escalation study. patients receive e7070 iv over 1 hour once every 3 weeks. treatment continues for at least 2 courses in the absence of disease progression or unacceptable toxicity. cohorts of 3-6 patients receive escalating doses of e7070 until the maximum tolerated dose (mtd) is determined. the mtd is defined as the dose preceding that at which at least 2 of 6 patients experience dose limiting toxicity. projected accrual: approximately 30 patients will be accrued for this study within 12 months.

Eligibility criteria:
disease characteristics: histologically or cytologically confirmed solid tumor not amenable to standard therapy no brain tumor involvement or leptomeningeal disease patient characteristics: age: 18 to 70 performance status: who 0-2 life expectancy: at least 3 months hematopoietic: absolute neutrophil count at least 1,500/mm3 platelet count at least 100,000/mm3 hemoglobin at least 9 g/dl hepatic: bilirubin less than 1.5 mg/dl transaminases and alkaline phosphatase no greater than 2.5 times upper limit of normal (uln) (no greater than 5 times uln for liver metastases) renal: creatinine no greater than 1.4 mg/dl or creatinine clearance at least 60 ml/min other: no active bacterial infections (e.g., abscess or fistula) no other nonmalignant disease that precludes protocol therapy no history of alcoholism, drug addiction, or psychotic disorders that would prevent compliance no glaucoma not pregnant or nursing fertile patients must use effective contraception prior concurrent therapy: biologic therapy: at least 4 weeks since prior immunotherapy chemotherapy: at least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) endocrine therapy: at least 4 weeks since prior anticancer hormonal therapy radiotherapy: at least 4 weeks since prior radiotherapy (6 weeks for extensive radiotherapy) no concurrent radiotherapy except for localized palliation surgery: not specified other: no other concurrent investigational drugs or antitumor drugs no sulphonylureas or anti-arrhythmic agents

Keywords: unspecified adult solid tumor, protocol specific
symptomatic efficacy of diacerein in knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: pain is the main symptom of osteoarthritis that motivates medical visits. diacerhein has already demonstrated its efficacy in knee and/or hip osteoarthritis. this study aims at confirming the efficacy of diacerhein in symptomatic knee osteoarthritis using known and validated criteria and according to the recommendations and guidelines for this kind of study.


Eligibility criteria:
inclusion criteria: * painful primary osteoarthritis (vas ≥ 40 mm) * radiologically proven (kellgren \& lawrence grade i to iii) * requiring the prescription of a symptomatic treatment of pain exclusion criteria: * severe associated diseases * wash-out: ains, coxibs, paracetamol, anti-osteoarthritic treatments, hyaluronic acid, knee tidal lavage * other osteoarticular disease

Keywords: osteoarthritis knee diacerein painful osteoarthritis clinical trial
risk of asthma in infants with atopic dermatitis

Conditions: Asthma; Eczema; Dermatitis, Atopic

Summary: infants will be enrolled in this study if they have never been diagnosed with asthma or wheezing and have been diagnosed with atopic dermatitis or eczema. infants with some types of skin rashes are at high risk for developing asthma by 6 years of age. the purpose of this study is to determine whether we can identify infants who will develop asthma.

asthma is a disease characterized by recurrent episodes of wheezing, inflammation of the airways, and airways that are very sensitive to stimulation (hyper-responsiveness). symptoms of asthma frequently begin in early childhood; however, it has been difficult to identify pre-symptomatic, at-risk infants and toddlers. family history of asthma and allergy is strongly associated with the early onset and persistence of asthma symptoms, and children with early onset persistent asthma are more likely to demonstrate allergies. the development of allergic disease results from complex interactions between genetic susceptibility and environmental factors; however, infants with atopic dermatitis have a 50% chance of developing asthma by 6 years of age. airway inflammation and airway hyper-responsiveness are characteristics of asthmatic children. we plan to evaluate whether infants with allergic dermatitis have evidence of airway inflammation and hyper-responsiveness, and whether cells from the blood and the nose are also hyper-responsive to stimulation prior to the onset of clinical symptoms of asthma. in addition we will evaluate whether certain genetic profiles are associated with allergic disease in infants.

Eligibility criteria:
inclusion criteria- 1. full term infants born greater than 37 weeks 2. history of atopic dermatitis or eczema exclusion criteria 1. heart disease 2. asthma 3. respiratory illness such as rsv, bronchiolitis or croup 4. hospitalization for respiratory illness 5. history of wheezing

Keywords: asthma eczema dermatitis, atopic infant
postural instability in progressive supranuclear palsy

Conditions: Progressive Supranuclear Palsy; Parkinson's Disease

Summary: the purpose of this study is to better understand why individuals with progressive supranuclear palsy (psp) fall. understanding the mechanism of gait and balance dysfunction in individuals with psp may provide us with important early diagnostic tools, allowing for earlier identification of mobility problems and to better evaluate medical therapies aimed at improving motor disability. the investigators will recruit 10 psp, 10 pd and 10 healthy controls for the study. all subjects will be asked to come to the ohsu clinic at the center for health and healing for an initial screening visit. they will meet with the primary investigator to conduct a brief interview and physical examination. in addition, they will be asked to answer questions regarding current and past medical illness, how often they fall and what kinds of medications they are on. subjects who agree to participate will come to the oregon clinical and translational research institute (octri) at ohsu for balance testing. subjects will be asked to stand or sit on a movable platform with eyes open or closed. prior to standing on the platform, the investigators will place 6 small sensors on body which are held in place by velcro straps (one on each wrist, ankles, chest and lower back). the platform will then be moved (tilt or slide) while subjects try to keep their balance. during all of the balance tests described above, body movements will be recorded from the sensors on the subjects' body. this data is directly recorded by a computer and analyzed to help us gain better understanding of the subjects' posture and their ability to remain up right.


Eligibility criteria:
inclusion criteria: 1. diagnosis of probable or possible psp as defined by the national institute of neurological disorders and stroke and society for progressive supranuclear palsy (ninds-spsp) diagnostic criteria. 2. be able to ambulate and stand unassisted for 5 minutes 3. be able to cooperate with gait and balance testing 4. be able to give informed consent. exclusion criteria: 1. cannot exhibit behavior or have dementia that precludes participation in the protocol 2. cannot have medical or orthopedic illness that, in the investigator's opinion, would impact the patient's postural control or ability to participate in the study.

Keywords: progressive supranuclear palsy psp falls gait balance parkinson's disease pd
study of "continuous use" of celecoxib vs. "usual or intermittent use"

Conditions: Osteoarthritis, Knee; Osteoarthritis, Hip

Summary: to determine whether "continuous use" of celecoxib over a 6-month period is more efficacious than "usual or intermittent use" in preventing spontaneous osteoarthritis flares of the knee and hip.


Eligibility criteria:
inclusion criteria: * subject has been diagnosed, according to american college of rheumatology guidelines, with osteoarthritis of the hip or knee and requires non-steroidal anti-inflammatory drugs (nsaids) to control their osteoarthritis pain and have access to a touch-tone telephone. exclusion criteria: * subject has had surgery on index joint. * subject has history of rheumatoid arthritis or fibromyalgia syndrome. * subject has active gastrointestinal or cardiovascular disease.

Keywords: chronic treatment osteoarthritis, celecoxib, continuous use, intermittent use
rhabdoid tumors cellular architecture by single-cell analyses (innovrt-2)

Conditions: ATRT

Summary: the aim is to describe at the cellular level the heterogeneity of rhabdoid tumors, and identify how this diversity influences resistance to treatment.

rhabdoid tumors are aggressive cancers of infancy. although frequently chemosensitive at the very beginning, they very often show resistance, suggesting some intra-tumor diversity or plasticity. moreover, morphological analysis of rhadoid tumors often reveal some variety in tumor cell shapes and immunohistochemical profiling. altogether, this suggests some intra-tumor heterogeneity, that has been scarcely studied so far. this project aims to describe the intra-tumor heterogeneity by single-cell sequencing approaches. after surgical resection, fresh tumor samples will be dissected and analysed using the 10x chromium technology. briefly, cells will be grouped in clusters according to their gene expression signalling, and each cluster will be defined in comparison with all other ones. differential analyses will allow identifying the main characteristic of each cell sub-population. potential filiations between clusters will be analysed using classical algorithms. the study will be performed on 10 to 15 tumor samples.

Eligibility criteria:
inclusion criteria: * aged 0-17 years old * having a rhabdoid tumor according to clinical and radiological features or likely having a rhabdoid tumor according to clinical and radiological features * surgical resection in standard care * sufficient material for both diagnosis and experimental procedures * parents' agreement

Keywords: atrt smarcb1 single-cell rnaseq
risk of cesarean section in primiparous women over 35 years of age.

Conditions: Pregnancy Complications

Summary: the investigators reviewed saint thomas maternity hospital's database during a 5 year period and compared two cohorts of patients (primiparous women over 35 years of age and primiparous woman between 20 and 34 years of age). the objective was to determine the risk of cesarean section and other perinatal complications between the groups.


Eligibility criteria:
inclusion criteria: * pregnant primiparous women. * birth after 22 weeks and neonatal weight \> 501g. exclusion criteria: * multiparity. * birth before 22 weeks or neonatal weight \< 500g.

Keywords: older women (>35 years of age) primipara cesarean section
inhaled milrinone in cardiac surgery

Conditions: Pulmonary Hypertension

Summary: the purpose of this study is to investigate the concentration-effect relationship of inhaled milrinone after prophylactic administration in cardiac surgical patients with preoperative pulmonary hypertension undergoing cardiopulmonary bypass.

milrinone elimination will be verify with blood and urine samples analysis.

Eligibility criteria:
inclusion criteria: * patients scheduled for elective cardiac surgery under cpb * high risk patients: nyha class ii-iii * preoperative diagnostic of pulmonary hypertension: * systolic pulmonary artery pressure (spap) \> 35 mm hg; or * mean pulmonary artery pressure (mpap) \> 25 mm hg; or * map/mpap \< 3.0 (after induction of anesthesia). exclusion criteria: * open heart surgery * contraindication to transesophageal echocardiography (tee) * hemodynamic instability before surgery * emergency surgery

Keywords: pulmonary hypertension cardiac surgery cardiopulmonary bypass (cpb)